The FDA has approved durvalumab (Imfinzi) plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for the treatment ...
AVZO-103 has received fast track designation for treating urothelial cancer patients previously treated with enfortumab ...
A phase 2 study reveals high efficacy and manageable safety of venetoclax plus obinutuzumab for untreated CLL/SLL in Japanese ...
The PACIFIC-2 trial reveals that durvalumab with chemoradiotherapy offers no survival benefits for stage 3 NSCLC and ...
A recent study reveals cognitive behavioral therapy significantly enhances lung cancer patients' ability to manage dyspnea ...
Benjamin George, MD, has significantly improved cancer care access in rural Nebraska, Colorado, and Kansas, transforming ...
Recent polling shows oncologists changing inclination in treatment for mHSPC based on tolerability profiles.
Selinexor-based regimens enhance T-cell activation in RRMM patients, without increasing inhibitory checkpoint molecules, indicating resistance is not due to T-cell exhaustion. Baseline protein ...
The median BMI of the cohort was 26.7 kg/m 2 (range, 17.9–55.2). Patients were classified into 3 main weight categories based ...
Findings from a recent clinical study (NCT05304793) show that cognitive behavioral therapy (CBT) can help patients with lung ...
RP1 and nivolumab combination achieved a 32.9% objective response rate and 15.0% complete response rate in advanced melanoma ...
During a live event, Praneeth Baratam, MBBS, discussed the molecular factors that affect staging of lower-risk myelodysplastic syndromes.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback